Clinical trial
Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer
NCT00003025 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003025 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer |
| Official title | A Phase I Pilot Trial of Immunotherapy With Autologous Tumor-Derived gp96 Heat Shock Protein - Peptide Complex (HSPPC-96) in Patients With Resected Pancreatic Adenocarcinoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | vitespen |
| Enrollment | 16 |
| Start date | Mar 1, 1997 |
| Primary completion | Jul 1, 2002 |
| Completion | Jul 1, 2002 |
| First posted | Aug 12, 2004 |
| Last update posted | Jul 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: